MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/antibiotics15050519

Медицинская библиотека · Antibiotics (Basel, Switzerland) · 2026

Expanding Diagnostic Options for Pediatric Meningitis: BCID2 Testing Results on Cerebrospinal Fluid After a Negative Meningitis/Encephalitis Panel.

Cortazzo Venere, Romani Lorenza, Vrenna Gianluca, Luca Maia De, Agosta Marilena, Rossitto Martina, Fox Valeria, Lucignano Barbara, Onori Manuela, Mercadante Stefania, Tommaso Vito, Lancella Laura, Bernardi Stefania, Pisani Mara, Salvatori Alessandra, Villani Alberto, Raponi Massimiliano, Perno Carlo Federico, Bernaschi Paola

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Rapid etiological diagnosis of bacterial meningitis is crucial in children, as delays can lead to neurological sequelae. The BioFire FilmArray Meningitis/Encephalitis (ME) panel is widely used on cerebrospinal fluid (CSF), but its target spectrum may miss healthcare-associated or multidrug-resistant pathogens. We evaluated the diagnostic performance and stewardship-oriented clinical impact of off-label BioFire FilmArray Blood Culture Identification 2 (BCID2) testing on CSF from pediatric patients with suspected bacterial CNS infection and negative ME results.

METHODS

We retrospectively analyzed CSF samples collected between January 2023 and March 2025 at a tertiary pediatric hospital. In ME-negative cases with persistent suspicion and abnormal CSF parameters, BCID2 was performed off-label on residual CSF aliquots after routine testing, without additional sampling. We assessed pathogen detection, agreement with culture, resistance-gene identification, and documented stewardship actions.

RESULTS

Among 76 ME-negative CSF samples tested with BCID2, 23 (30.3%) were positive, all involving organisms not included in the ME panel. BCID2 was concordant with culture in 19/23 cases (82.6%); 4/23 (17.4%) were BCID2-positive/culture-negative, consistent with reduced culture sensitivity in frequently pretreated cases. Resistance genes (VIM, vanA/B, CTX-M) were detected in 30.4% of BCID2-positive samples. Overall agreement with culture was 94.7% (PPA 100%, NPA 93.0%). Escalation was documented in 13/23 episodes (56.5%), discontinuation in 2/23 (8.7%), and confirmation in 9/23 (39.1%), with no de-escalation events; clinical outcomes were not systematically available.

CONCLUSIONS

In selected ME-negative pediatric cases with abnormal CSF profiles, BCID2 testing on residual CSF provided rapid, clinically meaningful microbiological information that may support antimicrobial optimization.

Для цитирования: Cortazzo Venere, Romani Lorenza, Vrenna Gianluca, Luca Maia De, Agosta Marilena, Rossitto Martina, Fox Valeria, Lucignano Barbara, Onori Manuela, Mercadante Stefania, Tommaso Vito, Lancella Laura, Bernardi Stefania, Pisani Mara, Salvatori Alessandra, Villani Alberto, Raponi Massimiliano, Perno Carlo Federico, Bernaschi Paola. Expanding Diagnostic Options for Pediatric Meningitis: BCID2 Testing Results on Cerebrospinal Fluid After a Negative Meningitis/Encephalitis Panel.. Antibiotics (Basel, Switzerland). 2026. DOI: 10.3390/antibiotics15050519.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.